A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
== Cause == A seroma is usually caused by surgery. Seromas are particularly common after breast surgery (e.g., mastectomy), abdominal surgery, and reconstructive surgery. It can also be seen after neck surgery, thyroid and parathyroid surgery, and hernia repair. The larger the surgical intervention, the more likely that seromas form. Early or improper removal of sutures can sometimes lead to formation of seroma or discharge of serous fluid from operative areas. Seromas can also sometimes be caused by injury, such as when the initial swelling from a blow or fall does not fully subside. The remaining serous fluid causes a seroma that the body usually absorbs gradually over time (often taking many days or weeks), but a knot of calcified tissue sometimes remains. Large seromas take longer to resolve than small ones, and they are more likely to undergo secondary infection. A seroma may persist for several months, or even years as the surrounding tissue hardens. Seroma is the most common surgical complication after breast surgery. It is due to the presence of rich lymphatic system in the breast, low fibrinogen levels in lymph fluid and potential space creation in the breast after surgery, which contributes to seroma formation. Seroma is more common in older and obese people.
In 2021, FAO released the first definition of agrifood systems and agrifood systems' resilience in The State of Food and Agriculture 2021 – Making agrifood systems more resilient to shocks and stresses. The definition of agrifood systems' resilience is adapted from Tendall et al.'s definition of food system resilience, which is "capacity over time of a food system and its units at multiple levels, to provide sufficient, appropriate and accessible food to all, in the face of various and even unforeseen disturbances". Agrifood systems are broader than food systems, as these encompass the entire range of actors and their interlinked value-adding activities in the primary production of food and non-food agricultural products, as well as in food storage, aggregation, post-harvest handling, transportation, processing, distribution, marketing, disposal and consumption.
William Turner's Historia Avium (History of Birds), published at Cologne in 1544, was an early ornithological work from England. He noted the commonness of kites in English cities where they snatched food out of the hands of children. He included folk beliefs such as those of anglers. Anglers believed that the osprey emptied their fishponds and would kill them, mixing the flesh of the osprey into their fish bait. Turner's work reflected the violent times in which he lived, and stands in contrast to later works such as Gilbert White's 1789 The Natural History and Antiquities of Selborne which were written in a tranquil era. In the 17th century, Francis Willughby (1635–1672) and John Ray (1627–1705) created the first major system of bird classification that was based on function and morphology rather than on form or behaviour. Willughby's Ornithologiae libri tres (1676) completed by John Ray is sometimes considered to mark the beginning of scientific ornithology. Ray also worked on Ornithologia, which was published posthumously in 1713 as Synopsis methodica avium et piscium. The earliest list of British birds, Pinax Rerum Naturalium Britannicarum, was written by Christopher Merrett in 1667, but authors such as John Ray considered it of little value. Ray did, however, value the expertise of the naturalist Sir Thomas Browne (1605–1682), who not only answered his queries on ornithological identification and nomenclature, but also those of Willoughby and Merrett in letter correspondence.
In 2024, Sinclair resigned as the President of The Academy for Health and Lifespan Research, an organization made up of a group of scientists that Sinclair had co-founded. The resignation came after what The Wall Street Journal described as a "cascade" of resignations from outraged members of The Academy after Sinclair and his brother announced that Animal Bioscience had proven that a supplement for dogs with undisclosed ingredients reversed aging. The claim was also met with criticism and skepticism from other longevity researchers.
transfer-messenger RNA (tmRNA) A type of RNA molecule in some bacteria which has dual tRNA-like and mRNA-like properties, allowing it to simultaneously perform a number of different functions during translation.
Sources: en.wikipedia.org
Hyperinsulinemic hypoglycemia describes the condition and effects of low blood glucose caused by excessive insulin. Hypoglycemia due to excess insulin is the most common type of serious hypoglycemia. It can be due to endogenous or injected insulin.
By September 1604, Dmitri I had gathered a force of 2,500 men, of whom 1,400 were Cossacks. Two thirds of these "cossacks", however, were in fact Ukrainian civilians, only 500 being professional Ukrainian Cossacks. On July 4, 1610, 4,000 Ukrainian Cossacks fought in the Battle of Klushino, on the side of the Polish-Lithuanian Commonwealth. They helped to defeat a combined Muscovite-Swedish army and facilitate the occupation of Moscow from 1610 to 1611, riding into Moscow with Stanisław Żółkiewski. The final attempt by King Sigismund and Wladyslav to seize the throne of Muscovy was launched on April 6, 1617. Although Wladyslav was the nominal leader, it was Jan Karol Chodkiewicz who commanded the Commonwealth forces. By October, the towns of Dorogobuzh and Vyazma had surrendered. But a defeat, when the counterattack on Moscow by Chodkiewicz failed between Vyasma and Mozhaysk, prompted the Polish-Lithuanian army to retreat. In 1618, Petro Konashevych-Sahaidachny continued his campaign against the Tsardom of Russia on behalf of the Cossacks and the Polish-Lithuanian Commonwealth. Numerous Russian towns were sacked, including Livny and Yelets. In September 1618, with Chodkiewicz, Konashevych-Sahaidachny laid siege to Moscow, but peace was secured.
Magnesium is the third-most-commonly-used structural metal, following iron and aluminium. The main applications of magnesium are, in order: aluminium alloys, die-casting (alloyed with zinc), removing sulfur in the production of iron and steel, and the production of titanium in the Kroll process. Magnesium is used in lightweight materials and alloys. For example, when infused with silicon carbide nanoparticles, it has extremely high specific strength. Historically, magnesium was one of the main aerospace construction metals and was used for German military aircraft as early as World War I and extensively for German aircraft in World War II. The Germans coined the name "Elektron" for magnesium alloy, a term which is still used today. In the commercial aerospace industry, magnesium was generally restricted to engine-related components, due to fire and corrosion hazards. Magnesium alloy use in aerospace is increasing in the 21st century, driven by the importance of fuel economy. Magnesium alloys can act as replacements for aluminium and steel alloys in structural applications.
Another area he developed was porpos polymers from high internal phase emulsions (PolyHIPEs), particularly as applied to solid phase peptide synthesis. Sherrington returned to Strathclyde in 1987 as a full professor and later the head of the organic chemistry section. His reputation grew and he was to hold visiting chairs in 10 universities around the world. He was awarded a DSc by his alma mater, and elected a Fellow of the Royal Societies of Edinburgh and London. In their memoir of Sherrington Randal W. Richards and Philip Hodge note, that “It is very evident that David Sherrington made a major and unique impact on polymer science by enthusiastically bringing the rigour of physical chemistry to a new and rapidly expanding area of the subject and by being keen to collaborate with experts in other Disciplines”. David Colin Carrington suffered from pain in his lower back for many years, and was finally diagnosed in April 2012 as having multiple system atrophy (MSA). He had two major attacks of pneumonia in 2014 and died on 4 October, survived by Val. They had no children. Val has continued to raise awareness of MSA.
Sources: en.wikipedia.org
Some software packages such as Markerview include multivariate statistical analysis (for example, principal component analysis) and these will be helpful for the identification of correlations in lipid metabolites that are associated with a physiological phenotype, in particular for the development of lipid-based biomarkers. Another objective of the information technology side of lipidomics involves the construction of metabolic maps from data on lipid structures and lipid-related protein and genes. Some of these lipid pathways are extremely complex, for example the mammalian glycosphingolipid pathway. The establishment of searchable and interactive databases of lipids and lipid-related genes/proteins is also an extremely important resource as a reference for the lipidomics community. Integration of these databases with MS and other experimental data, as well as with metabolic networks offers an opportunity to devise therapeutic strategies to prevent or reverse these pathological states involving dysfunction of lipid-related processes.
== Catalysis == The sortase B enzyme catalyzes a cell wall sorting reaction with a surface protein where a signal NXTN motif is cleaved. In the result, the C-end of the protein is covalently attached to a pentaglycine cross-bridge through an amide linkage, thus tethering the C-terminus of protein A to the cell wall. It cleaves the protein precursor molecule at the NPQTN motif. The peptide bond between T and N of the NPQTN sorting motif is cleaved to form a tetrahedral acyl intermediate. The amino groups of the pentaglycine cross-bridges linked to the lipid II peptidoglycan precursor molecules are thought to function as nucleophile resolving acyl intermediates and creating an amide bond between the surface protein and lipid II with subsequent incorporation of this intermediate into the cell wall envelope. IsdC remains buried within the cell wall, not surface located like IsdA and IsdB anchored by Sortase A. This whole system work together to scavenge iron from haemoglobin.
== Work == From 1946 through 1956 Ettre worked at pharmaceutical and chemical engineering firms in Hungary. In 1956 he was appointed to the position of head of the Industrial Department of the Hungarian Research Institute on Plastics in Budapest. He held the position of chemical engineer at Lurgi AG in Frankfurt am Main, West Germany, where he began to work with gas chromatography. In the United States, Ettre worked at the PerkinElmer Corporation from 1958 until his retirement in 1990; he held the positions of Application Engineer, Product Specialist, Chief Applications Chemist, and Senior Staff Scientist, and finally Senior Scientist. Ettre's major research area was chromatography. His activities covered a variety of fields including surface area studies, trace analysis, detector response, reaction gas chromatography, the retention index system, headspace gas chromatography, and in particular the theory and practice of open-tubular (capillary) column gas chromatography. After his retirement, he focused on the history and evolution of chromatography and its relationship to other scientific disciplines. The history and variations of Hungarian philately in the period 1900–1944 was one of his lesser-known activities, in which he authored several monographs published by the Society for Hungarian Philately.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.